Search Results for: biotime

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

Mesoblast-stock

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner …

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy

Cell-Cure-Logo

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based …

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy Read More »

Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program

BioTime (BTX), via its subsidiary Asterias, has formally purchased the Geron (GERN) embryonic stem cell (ESC) research program and assets. Incidentally, Asterias in nature refers to a genus of sea stars including starfish and you can see it in their logo. Perhaps this was chosen given the amazing regenerative capacity of starfish? You may recall …

Great news: BioTime Subsidiary Asterias Acquires Geron Embryonic Stem Cell Program Read More »

BioTime CEO Mike West Interview Part 2: Geron & hESC

Michael-West-PhD-CEO-of-BioTime-1-934x10241

When you want to both know the real history of the pluripotent stem cell-based biotech industry and perspectives on its future, there are only a handful of people to turn to and one of them is definitely Dr. Michael West, CEO of BioTime. I’m doing a several part series of blog posts on a lengthy …

BioTime CEO Mike West Interview Part 2: Geron & hESC Read More »

Interview with BioTime CEO Michael West Part 1: a little stem cell history

Michael-West-PhD-CEO-of-BioTime-1-934x10241

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock …

Interview with BioTime CEO Michael West Part 1: a little stem cell history Read More »

A great day for stem cell research: more on SCOTUS & details on BioTime news

Today the Supreme Court announced it would not hear the Sherley v Sebelius case, ending the court battle that has left embryonic stem cell research (ESCR) in what I’ve called a “big chill”. This is great news. It is all over the mainstream media. Even the rampant anti-science, pro-lifers have declared defeat. I’m not going …

A great day for stem cell research: more on SCOTUS & details on BioTime news Read More »

CIRM comment on prospect of BioTime buying Geron stem cell program

When biotech Geron punted on its embryonic stem cell (ESC) program despite having an ongoing FDA-approved clinical trial for spinal cord injury and tens of millions in loan funding from CIRM, many in the stem cell field were upset to put it mildly. Geron repaid the CIRM loan with interest. At the time, the general …

CIRM comment on prospect of BioTime buying Geron stem cell program Read More »

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell therapy arena. Today …

24 cell therapy & stem cell stocks I’m following Read More »

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36

Peter-Marks-Regenerative-Medicine-Advanced-Therapy-Designation-RMAT-

This post includes my updated list of firms/products that have received FDA regenerative medicine advanced therapy designation or RMAT, which are in the public domain. The numbers really jumped in the last month. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm …

FDA Regenerative Medicine Advanced Therapy RMAT designations jump to 36 Read More »

RMAT List (51)

FDA-RMAT

Here is a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. I’m assuming for the purposes of this resource page that all self-reports are accurate. Note that the links embedded into the firm names are to relevant press releases. A special thanks to some folks …

RMAT List (51) Read More »